Potential of Peroxisome Proliferator-Activated Receptor Gamma Antagonist Compounds as Therapeutic Agents for a Wide Range of Cancer Types

被引:60
作者
Burton, Jack D. [1 ,2 ]
Goldenberg, David M. [2 ]
Blumenthal, Rosalyn D. [2 ]
机构
[1] Coney Isl Hosp, Brooklyn, NY 11235 USA
[2] Ctr Mol Med & Immunol, Belleville, NJ 07109 USA
关键词
D O I
10.1155/2008/494161
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
PPAR gamma is a therapeutic target that has been exploited for treatment of type II diabetes mellitus (T2DM) with agonist drugs. Since PPAR gamma is expressed by many hematopoietic, mesodermal and epithelial cancers, agonist drugs were tested and shown to have both preclinical and clinical anticancer activity. While preclinical activity has been observed in many cancer types, clinical activity has been observed only in pilot and phase II trials in liposarcoma and prostate cancer. Most studies address agonist compounds, with substantially fewer reports on anticancer effects of PPAR gamma antagonists. In cancer model systems, some effects of PPAR gamma agonists were not inhibited by PPAR gamma antagonists, suggesting noncanonical or PPAR gamma-independent mechanisms. In addition, PPAR gamma antagonists, such as T0070907 and GW9662, have exhibited antiproliferative effects on a broad range of hematopoietic and epithelial cell lines, usually with greater potency than agonists. Also, additive antiproliferative effects of combinations of agonist plus antagonist drugs were observed. Finally, there are preclinical in vivo data showing that antagonist compounds can be administered safely, with favorable metabolic effects as well as antitumor effects. Since PPAR gamma antagonists represent a new drug class that holds promise as a broadly applicable therapeutic approach for cancer treatment, it is the subject of this review. Copyright (C) 2008 Jack D. Burton et al.
引用
收藏
页数:7
相关论文
共 39 条
[1]   Curcurnin (diferuloylmethane) inhibits constitutive and IL-6-inducible STAT3 phosphorylation in human multiple myeloma cells [J].
Bharti, AC ;
Donato, N ;
Aggarwal, BB .
JOURNAL OF IMMUNOLOGY, 2003, 171 (07) :3863-3871
[2]   Bisphenol A diglycidyl ether (BADGE) is a PPARγ agonist in an ECV304 cell line [J].
Bishop-Bailey, D ;
Hla, T ;
Warner, TD .
BRITISH JOURNAL OF PHARMACOLOGY, 2000, 131 (04) :651-654
[3]   Peroxisome proliferator-activated receptor-γ antagonists exhibit potent antiproliferative effects versus many hematopoietic and epithelial cancer cell lines [J].
Burton, Jack D. ;
Castillo, Mary E. ;
Goldenberg, David M. ;
Blumenthal, Rosalyn D. .
ANTI-CANCER DRUGS, 2007, 18 (05) :525-534
[4]   CD74 is expressed by multiple myeloma and is a promising target for therapy [J].
Burton, JD ;
Ely, S ;
Reddy, PK ;
Stein, R ;
Gold, DV ;
Cardillo, TM ;
Goldenberg, DM .
CLINICAL CANCER RESEARCH, 2004, 10 (19) :6606-6611
[5]   IDENTIFICATION OF 2 MESSENGER PPAR RELATED RECEPTORS AND EVIDENCE FOR THE EXISTENCE OF 5 SUBFAMILY MEMBERS [J].
CHEN, F ;
LAW, SW ;
OMALLEY, BW .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1993, 196 (02) :671-677
[6]   Peroxisome proliferator-activated receptor-γ antagonists GW9662 and T0070907 reduce the protective effects of lipopolysaccharide preconditioning against organ failure caused by endotoxemia [J].
Collin, M ;
Murch, O ;
Thiemermann, C .
CRITICAL CARE MEDICINE, 2006, 34 (04) :1131-1138
[7]   Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor-γ ligand troglitazone in patients with liposarcoma [J].
Demetri, GD ;
Fletcher, CDM ;
Mueller, E ;
Sarraf, P ;
Naujoks, R ;
Campbell, N ;
Spiegelman, BM ;
Singer, S .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (07) :3951-3956
[8]   Peroxisome proliferator-activated receptors and retinoic acid receptors differentially control the interactions of retinoid X receptor heterodimers with ligands, coactivators, and corepressors [J].
DiRenzo, J ;
Soderstrom, M ;
Kurokawa, R ;
Ogliastro, MH ;
Ricote, M ;
Ingrey, S ;
Horlein, A ;
Rosenfeld, MG ;
Glass, CK .
MOLECULAR AND CELLULAR BIOLOGY, 1997, 17 (04) :2166-2176
[9]   The nuclear eicosanoid receptor, PPARγ, is aberrantly expressed in colonic cancers [J].
DuBois, RN ;
Gupta, R ;
Brockman, J ;
Reddy, BS ;
Krakow, SL ;
Lazar, MA .
CARCINOGENESIS, 1998, 19 (01) :49-53
[10]   Bisphenol A diglycidyl ether induces apoptosis in tumour cells independently of peroxisome proliferator-activated receptor-γ, in caspase-dependent and -independent manners [J].
Fehlberg, S ;
Trautwein, S ;
Göke, A ;
Göke, R .
BIOCHEMICAL JOURNAL, 2002, 362 :573-578